Odonate Therapeutics, Inc.
OOTC:ODTCShare Statistics
As of December 31, 2021, Odonate Therapeutics, Inc. has 481.00 shares outstanding.
| Shares Outstanding | 481.00 |
Valuation Ratios
These figures are as of December 31, 2021.
| PB Ratio | 0.88 |
| P/TBV Ratio | 0.88 |
| P/FCF Ratio | -0.69 |
| P/OCF Ratio | -0.69 |
Financial Position
As of December 31, 2021, Odonate Therapeutics, Inc. maintains a current ratio of 4.75, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.75 |
| Quick Ratio | 4.35 |
| Debt / Equity | 7.87 |
| Debt / EBITDA | -0.06 |
Financial Efficiency
Over the twelve months ended December 31, 2021, Odonate Therapeutics, Inc. posted a negative return on equity (ROE) of -69.92, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -55.34, reflecting losses generated across the asset base.
| Return on Equity (ROE) | -69.92 |
| Return on Assets (ROA) | -55.34 |
Dividends & Yields
These figures cover the twelve months ended December 31, 2021. Free cash flow yield is negative at -145.72: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 24.54, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Odonate Therapeutics, Inc. shareholders.
| Shareholder Yield | 24.54 |
| FCF Yield | -145.72 |
Stock Splits
Odonate Therapeutics, Inc.'s most recent stock split took place on January 15, 2025 with a 8:1 split ratio.
| Last Split Date | 1/15/2025 |
| Split Ratio | 8:1 |
Scores
As of December 31, 2021, Odonate Therapeutics, Inc. has an Altman Z-Score of -8.50, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -8.50 |